Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network (Q36589035)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 September 2012

Language	Label	Description	Also known as
English	Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network	scientific article published on 25 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Nancy L Keating

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Rachel A Freedman

1

object named as

Rachel A Freedman

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2

object named as

Melissa E Hughes

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Rebecca A Ottesen

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jane C Weeks

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yulei He

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yu-Ning Wong

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Richard Theriault

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

25 September 2012

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

119

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

839-846

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Socioeconomic status and survival after an invasive breast cancer diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Completion of therapy by Medicare patients with stage III colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Missed opportunities: racial disparities in adjuvant breast cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Breast cancer trends among black and white women in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Doxorubicin cardiotoxicity in African Americans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

NCCN outcomes research database: data collection via the Internet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Epidemiology of anthracycline cardiotoxicity in children and adults.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

9 September 2017

Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

30 September 2017

Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

30 September 2017

Can comorbidity be measured by questionnaire rather than medical record review?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

30 September 2017

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565006

28 June 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Trends in racial and age disparities in definitive local therapy of early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Parity and disparity in first course treatment of invasive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Race, socioeconomic status, and breast cancer treatment and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27831

21 January 2018

Outcomes assessment in the NCCN

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duration of adjuvant chemotherapy for colon cancer and survival among the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re: Completion of therapy by Medicare patients with stage III colon cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011924

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27831

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36589035&oldid=2106022726"